Objectives To perform a systematic literature review (SLR) concerning the safety of synthetic
(s) and biological (b) disease-modifying anti rheumatic dugs (DMARDs) to inform the 2019 …

Currently, there is a growing interest in Janus kinase (JAK) intracellular signalling since
targeted inhibitors against these pathways are proving effective in the treatment of a range of …

Background To compare infectious risk between JAK inhibitors (JAKis) versus TNF inhibitors
(TNFis) among rheumatoid arthritis (RA) patients in Korea. Methods Using 2009–2019 …

Objectives Efficacy and safety of tofacitinib, an oral Janus kinase inhibitor, were evaluated in
a 6-month, double-blind, phase 3 study in Chinese patients with active (polyarthritic) …

Rheumatoid arthritis (RA) is a chronic inflammatory joint disease characterized by synovial
inflammation. Fibroblast‑like synoviocytes (FLS) serve a vital role in the initiation and …

Introduction Baricitinib is an oral selective inhibitor of Janus kinase (JAK) 1 and JAK 2, which
has demonstrated significant efficacy in patients with moderately to severely active …

The therapy of autoimmune rheumatological conditions has undergone significant changes
with the introduction of biologic anti-inflammatory agents including cytokine antagonists and …

Background Biological disease‐modifying antirheumatic drugs (bDMARDs) are treatment
options for refractory juvenile idiopathic arthritis (JIA) cases which cannot be afforded by the …

Background The efficacy and safety of the oral Janus kinase inhibitor peficitinib were
investigated in Asian patients with rheumatoid arthritis (RA). Methods In this double-blind …

Background Patients with moderate-to-severe rheumatoid arthritis have a heavy financial
burden. The cost-effectiveness of introducing tofacitinib to the current treatment sequence for …